Alto Neuroscience(NYSE) ANRO

Alto Neuroscience, Inc. makes personalized medicines for people with mental health conditions. It uses brain data to match patients with the right treatment. This helps doctors find the best medicine without guessing.

Personalized Drugs for Brain Health

• ALTO-207: Combination therapy for treatment-resistant depression designed to allow higher doses with fewer side effects.
• ALTO-300: Investigational antidepressant for patients who show specific signatures on brain wave tests; currently in Phase 2b trials.
• ALTO-100: Drug candidate for bipolar depression that targets brain plasticity, which is the brain's ability to adapt.
• ALTO-101: Treatment for cognitive issues in schizophrenia that aims to avoid common digestive side effects of similar drugs.
• ALTO-203: Small molecule medicine for patients with major depressive disorder who struggle to experience pleasure.

Strategic Growth and New Funding

• Acquired ALTO-207 and ALTO-208 from Chase Therapeutics Corporation in May 2025 to expand its drug pipeline.
• Raised approximately $114.8 million in net proceeds through a private placement transaction in March 2026.
• Generated roughly $94.6 million in net proceeds from a public stock offering completed in July 2026.
• Entered a convertible grant agreement with Wellcome in July 2024 to support treatments for bipolar depression.
• Launched a Phase 2b clinical trial for ALTO-207 in April 2026 focused on treatment-resistant depression.

The Precision Psychiatry Advantage

The company analyzes brain activity and behavioral patterns through its Precision Psychiatry Platform. This system uses artificial intelligence to find biological markers that predict which patients will respond best to specific drugs.

Financial Performance at a Glance

• Net loss was $27.6 million for the three months ended June 30, 2026, compared to $17.7 million in 2025.
• Research and development expenses totaled $42.4 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and restricted cash reached $244.2 million as of June 30, 2026.
• Accumulated deficit was $255.5 million as of June 30, 2026, due to ongoing clinical testing costs.
• Market capitalization was $1.0 billion according to the most recent company profile data.

Bottom Line

Alto Neuroscience is shifting psychiatric care from a trial-and-error approach to one based on individual biology. Its growing pipeline and focus on data-driven therapy aim to improve outcomes for patients with complex brain disorders.